AKESO Aktie

 

HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer......

There was HKD947.6 million, HKD607 million and HKD163.8 million Southbound Trading net inflow to MINIMAX-W (00100.HK), Z.AI (02513.HK) and KB LAMINATES (01888.HK).There was HKD2.1 billion, HKD903.7 million and HKD831.5 million Southbound Trading net outflow from TENCENT (00700.HK), SMIC (00981.HK) and AKESO (09926.HK).For Southb......

CICC issued a report stating that AKESO (09926.HK) announced its results for 1H26, with revenue of RMB1.806 billion, up 27.9% YoY, while net loss attributable to shareholders reached RMB424 million, in line with the broker's expectations. AK112 was approved in August this year for first-line squamous non-small cell lung cancer t......

Daiwa issued a research report stating that the preset interim overall survival (OS) analysis for AKESO (09926.HK)'s Phase III study of ivonescimab as first-line treatment for PD-L1-positive NSCLC, as assessed by the Independent Data Monitoring Committee, showed that the study achieved its key secondary endpoint of OS. Daiwa bel......

AKESO (09926.HK) announced that the interim analysis of overall survival (OS), a pre-specified assessment conducted by the Independent Data Monitoring Committee, showed that the Phase III HARMONi-2 clinical study of its self-developed, globally first-in-class bispecific antibody "Ivonescimab" (PD-1/VEGF) versus pembrolizumab (Ke......

HONG KONG, Sept. 2, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee (IDMC), met the key......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

CMBI published a research report stating that AKESO (09926.HK)'s product sales revenue in the first half of the year reached approximately RMB1.8 billion, representing only 37% of the broker's previous full-year forecast and falling below expectations. Its cadonilimab (AK104) and ivonescimab (AK112) obtained broader medical insu......

D Bkg issued a research report saying that AKESO (09926.HK)'s revenue for 1H26 increased 27.9% YoY to RMB1.806 billion, representing only 27% of the broker's full-year forecast and 36% of market forecasts, missing expectations. During the period, driven by increased sales after AK104 and AK114 were included in the National Reimb......

CLSA said in a report that AKESO (09926.HK)'s sales rose 32.4% YoY in the first half of the year, while net loss narrowed 25.6% YoY, both missing market expectations. Following the results, the broker revised its forecasts and lowered the TP from HKD180.9 to HKD177.8. It maintained the Outperform rating.The report noted that AKE......

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC....

Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca's Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso's ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China's biopharma industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and chemotherapy against......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) of the randomized, controlled, double-blinded, multicenter, registrational......

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of......